Children Age Articles & Analysis: Older
87 news found
Leisure activities included go-kart racing, Laser Tag games and bowling in a complete recreational park for children of all ages. The programme included raffles for Brazilian football team t-shirts, balls and backpacks, among other gifts alluding to Brazil Click here to read the full ...
(Tris), a commercial-stage biopharmaceutical company focused on ADHD, pain, addiction and neurological disorders, today announced that Health Canada has authorized the use of Quillivant® ER (extended release) for the treatment of attention deficit hyperactivity disorder (ADHD) in children ages 6 to 12. Quillivant ER will be available as both an oral ...
Xarelto is approved for more venous and arterial thromboembolic (VAT) conditions than any other NOAC: The prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (AF) with one or more risk factors The treatment of pulmonary embolism (PE) in adults The treatment of deep vein thrombosis (DVT) in adults The prevention of recurrent PE and/or DVT in ...
ByBayer AG
Michael Devoy, Head of Medical Affairs & Pharmacovigilance of Bayer AG's Pharmaceuticals Division and Chief Medical Officer at Bayer. "Xarelto shows a significant benefit in patients with PAD who remain at high risk for major thrombotic events post lower extremity revascularization. ...
ByBayer AG
In the long run, it can also help treat childhood pneumonia (one of the main causes of death in children under the age of five) and hypooxia (an important sign of death). ...
Approximately 500 Canadians ages 6-11 are now eligible for TRIKAFTA®- Vertex has submitted this indication to CADTH & INESSS for Health Technology Assessments- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Health Canada has granted Marketing Authorization for the expanded use of TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) ...
It is not known if DUPIXENT is safe and effective in children with atopic dermatitis under 6 years of age. with other asthma medicines for the maintenance treatment of moderate-to-severe eosinophilic or oral steroid dependent asthma in adults and children 6 years of age and older whose asthma is not controlled with their current ...
About The TAPESTRY Study Axial is evaluating AB-2004 in the TAPESTRY study, a global, randomized, double-blind, placebo-controlled Phase 2b clinical trial to assess the efficacy, safety, and tolerability of the drug in children aged 13 to 17 who have been diagnosed with ASD and exhibit high irritability. ...
Visby Medical, Inc. an innovative diagnostic company, today announced its agreement with Urgent Care for Children (UC4C) to offer the company’s new Sexual Health Click Test to patients for the detection of sexually transmitted infections (STIs) in female patients 14 years of age and older. ...
B244 reduced patients’ WI-NRS score by an average of 34.3% and achieved clinically meaningful 4-point itch response Lesional severity (appearance) improved for IGA and EASI Results were achieved in 4 weeks Safe and well tolerated with no SAEs and no single adverse event occurred in greater than 1% of the active group. AOBiome Therapeutics, a clinical stage biotechnology company ...
The Phase 2b trial (www.theautismstudy.com) will evaluate the efficacy, safety, and tolerability of AB-2004 in children aged 13 to 17 who have been diagnosed with ASD and gastrointestinal symptoms. ...
SERB and BTG Specialty Pharmaceuticals announced that the European Commission has granted marketing authorisation for Voraxaze (glucarpidase) to reduce toxic plasma methotrexate concentration in adults and children (aged 28 days and older) with delayed methotrexate elimination or at risk of methotrexate toxicity. ...
To be considered equivalent, pediatric participants needed to achieve comparable GMT’s to those generated by adults in a large phase 3 clinical trial. At Day 56, across all ages, the mean SARS-CoV-2 antibody GMT was more than 30% higher in children aged 2-18 than the mean GMT from Phase 3 clinical trial involving 25,800 adult subjects ...
Xarelto is the only Factor Xa anticoagulant FDA approved for pediatric patients and offers a flexible weight-based dosing Xarelto is available in both oral tablet and liquid suspension formulations for use in appropriate children less than 18 years of age Convenient liquid formulation advances standard of care for children; alleviates ...
ByBayer AG
The Centers for Disease Control and Prevention (CDC) announced in late October that it had lowered the blood lead reference value (BLRV) for children in response to Lead Exposure Prevention and Advisory Committee (LEPAC) recommendations. ...
“Our mission is to better serve the children of Malawi, who deserve high quality healthcare and the latest medical technology, regardless of income or location,” said Madonna. ...
” Approximately 1 in 54 children in the U.S. and 1 in 160 children worldwide have been identified with ASD according to the Centers for Disease Control and Prevention (CDC) and World Health Organization (WHO), respectively. ...
SERB and BTG Specialty Pharmaceuticals today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending a marketing authorisation for Voraxaze (glucarpidase) to reduce toxic plasma methotrexate concentration in adults and children (aged 28 days and older) with delayed ...
In the United States, 7% of adults and 12% of children under the age of 18 years suffer from eczema and associated pruritus.1 Of these, approximately two thirds have mild to moderate cases. ...
About the AB-2004 Phase 2b Trial The Phase 2b trial is a global, randomized, double-blind, placebo-controlled study evaluating the efficacy, safety, and tolerability of AB-2004 in children aged 13 to 17 who have been diagnosed with ASD. The study will enroll an estimated 195 patients who will receive low or high doses of AB-2004 or placebo. ...